Guggenheim Securities adjusted its financial outlook for shares of AbbVie Inc . (NYSE:ABBV), reducing the price target to $212 from the previous $221, while still recommending a Buy rating for the ...
But unlike other low-cost ETFs that achieve a higher yield by targeting safe and stodgy low-growth companies, the Dividend ...
The list of 15 drugs ( up from 10 in 2023) includes four oncology drugs, three drugs targeting diabetes, two focused on COPD, ...
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...
The U.S. government targets 15 high-cost medications for Medicare price negotiations for 2027, under the Inflation Reduction ...
Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback